Symbiox Investment [SYMBIOX] vs Trident [TRIDENT] Detailed Stock Comparison
Symbiox Investment
BSE
Loading...
Trident
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Symbiox Investment wins in 9 metrics, Trident wins in 10 metrics, with 0 ties. Trident appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Symbiox Investment | Trident | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 34.63 | 33.75 | Trident |
| Price-to-Book Ratio | 0.27 | 3.31 | Symbiox Investment |
| Debt-to-Equity Ratio | 0.00 | 35.39 | Symbiox Investment |
| PEG Ratio | 0.04 | 0.42 | Symbiox Investment |
| EV/EBITDA | -15.06 | 16.33 | Symbiox Investment |
| Profit Margin (TTM) | 8.70% | 6.27% | Symbiox Investment |
| Operating Margin (TTM) | 19.32% | 11.49% | Symbiox Investment |
| EBITDA Margin (TTM) | 19.32% | 11.49% | Symbiox Investment |
| Return on Equity | 0.60% | 8.00% | Trident |
| Return on Assets (TTM) | 0.60% | 5.17% | Trident |
| Free Cash Flow (TTM) | $35.83M | $7.15B | Trident |
| Dividend Yield | N/A | 1.66% | N/A |
| 1-Year Return | -36.18% | -19.57% | Trident |
| Price-to-Sales Ratio (TTM) | 2.98 | 2.10 | Trident |
| Enterprise Value | $-51.07M | $158.26B | Trident |
| EV/Revenue Ratio | -1.76 | 2.28 | Symbiox Investment |
| Gross Profit Margin (TTM) | 49.18% | 51.29% | Trident |
| Revenue per Share (TTM) | $1 | $14 | Trident |
| Earnings per Share (Diluted) | $0.08 | $0.85 | Trident |
| Beta (Stock Volatility) | -1.22 | -0.05 | Symbiox Investment |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Symbiox Investment vs Trident Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Symbiox Investment | 0.36% | 2.97% | -2.12% | -4.81% | -17.56% | -47.34% |
| Trident | -1.92% | -4.75% | 3.50% | -9.18% | 16.53% | -15.27% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Symbiox Investment | -36.18% | -63.70% | 201.09% | -79.88% | -79.88% | -79.88% |
| Trident | -19.57% | -21.29% | 265.48% | 604.91% | 1,530.11% | 690.36% |
News Based Sentiment: Symbiox Investment vs Trident
Symbiox Investment
News based Sentiment: NEUTRAL
The month's events primarily consist of routine corporate governance activities – a board meeting, an AGM announcement, and a regulatory filing. While important for maintaining a healthy company structure, these events don't represent significant shifts in strategy or performance, resulting in a neutral overall sentiment.
Trident
News based Sentiment: POSITIVE
September was a strong month for Trident, highlighted by impressive Q1 FY26 financial results and continued strategic investment in Trident Global Corp. While market signals were mixed and Morningstar flagged high uncertainty, the overall narrative points to a company proactively addressing challenges and pursuing growth opportunities.
Performance & Financial Health Analysis: Symbiox Investment vs Trident
| Metric | SYMBIOX | TRIDENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹86.67M | ₹152.55B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 55,368 | 6,549,673 |
| 90 Day Avg. Volume | 57,405 | 5,838,472 |
| Last Close | ₹2.78 | ₹28.14 |
| 52 Week Range | ₹2.33 - ₹6.02 | ₹23.11 - ₹40.20 |
| % from 52W High | -53.82% | -30.00% |
| All-Time High | ₹26.20 (Feb 01, 2016) | ₹70.35 (Jan 17, 2022) |
| % from All-Time High | -89.39% | -60.00% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.47% | -0.02% |
| Quarterly Earnings Growth | 10.95% | 0.90% |
| Financial Health | ||
| Profit Margin (TTM) | 0.09% | 0.06% |
| Operating Margin (TTM) | 0.19% | 0.11% |
| Return on Equity (TTM) | 0.01% | 0.08% |
| Debt to Equity (MRQ) | 0.00 | 35.39 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹10.14 | ₹8.67 |
| Cash per Share (MRQ) | ₹4.40 | ₹1.31 |
| Operating Cash Flow (TTM) | ₹36.19M | ₹8.42B |
| Levered Free Cash Flow (TTM) | ₹1.92M | ₹3.70B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.66% |
| Last 12-Month Dividend | N/A | ₹0.50 |
Valuation & Enterprise Metrics Analysis: Symbiox Investment vs Trident
| Metric | SYMBIOX | TRIDENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 34.63 | 33.75 |
| Forward P/E | N/A | 23.91 |
| PEG Ratio | 0.04 | 0.42 |
| Price to Sales (TTM) | 2.98 | 2.10 |
| Price to Book (MRQ) | 0.27 | 3.31 |
| Market Capitalization | ||
| Market Capitalization | ₹86.67M | ₹152.55B |
| Enterprise Value | ₹-51,065,096 | ₹158.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -1.76 | 2.28 |
| Enterprise to EBITDA | -15.06 | 16.33 |
| Risk & Other Metrics | ||
| Beta | -1.22 | -0.05 |
| Book Value per Share (MRQ) | ₹10.14 | ₹8.67 |
Financial Statements Comparison: Symbiox Investment vs Trident
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SYMBIOX | TRIDENT |
|---|---|---|
| Revenue/Sales | ₹4.58M | ₹17.07B |
| Cost of Goods Sold | ₹2.33M | ₹8.31B |
| Gross Profit | ₹2.25M | ₹8.75B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹885,000 | ₹1.96B |
| EBITDA | ₹911,000 | ₹3.12B |
| Pre-Tax Income | ₹904,000 | ₹1.88B |
| Income Tax | ₹235,000 | ₹477.80M |
| Net Income (Profit) | ₹669,000 | ₹1.40B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SYMBIOX | TRIDENT |
|---|---|---|
| Cash & Equivalents | ₹10.59M | ₹663.40M |
| Total Current Assets | ₹319.51M | ₹25.10B |
| Total Current Liabilities | ₹2.42M | ₹12.50B |
| Long-Term Debt | ₹0 | ₹10.15B |
| Total Shareholders Equity | ₹317.24M | ₹46.21B |
| Retained Earnings | ₹3.93M | ₹26.84B |
| Property, Plant & Equipment | ₹151,563 | ₹99.20M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SYMBIOX | TRIDENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SYMBIOX | TRIDENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 55,368 | 6,549,673 |
| Average Daily Volume (90 Day) | 57,405 | 5,838,472 |
| Shares Outstanding | 31.29M | 5.08B |
| Float Shares | 24.61M | 1.20B |
| % Held by Insiders | 0.18% | 0.76% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Symbiox Investment vs Trident
| Metric | SYMBIOX | TRIDENT |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.50 |
| Last 12-Month Dividend Yield | N/A | 1.66% |
| 3-Year Avg Annual Dividend | N/A | ₹0.53 |
| 3-Year Avg Dividend Yield | N/A | 1.15% |
| 3-Year Total Dividends | N/A | ₹1.58 |
| Ex-Dividend Date | N/A | May 27, 2025 |